Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Skye to Contact Him Directly to Discuss Their Options If you purchased or acquired ...

Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with tirzepatide, in diet-induced obesity model New in vitro data demonstrates ...

Skye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s. Currently, Skye’s average price target ...

Punit S. Dhillon, President and CEO, highlighted the imminent reporting of Phase IIa data for nimacimab, describing the quarter as a "notable prelude to our reporting of our Phase IIa data for ...

Skye is focused on unlocking the pharmaceutical potential of the endocannabinoid system to treat diseases with metabolic, inflammatory, and fibrotic processes. Backed by leading life science venture ...

16-week top-line weight loss data validates mechanism of action targeting peripheral CB1 receptors Skye highlights safety advantages of large-molecule CB1 inhibition compared to small-molecule ...

Company: Skye Bioscience, Inc. (NYSE: SKYE) is a clinical stage biopharmaceutical company that focuses on developing molecules that modulate G protein-coupled receptors ("GPCRs") to treat obesity, ...

President and CEO Punit Dhillon reported that recent data from the Phase IIa CB1 study has "sharpened our focus, maintained our focus on our clinical path and strengthened our conviction in the ...

Enrollment completed in Phase 2a CBeyond™ trial of CB1 inhibitor, nimacimab, in obesity and overweight Faster-than-expected enrollment enables full top-line Phase 2a data in late Q3/early Q4 2025, ...

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.